lenvatinib
Sign in to saveAlso known as E 7080, ER-203492-00, Lenvima®, UNII-EE083865G2, E7080, 4-(3-Chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
In the Vinony graph
Within Vinony's link graph, lenvatinib is referenced by 500 other articles, and connects out to KIT proto-oncogene, receptor tyrosine kinase, VEGF receptors and CAS Registry Number.
Vinony files it under Carboxamides, Chemicals using indexlabels and Chloroarenes.
Its subject is documented across 14 Wikipedia language editions.
Research
4,069 papers- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.The New England journal of medicine · 2015
- Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy.Liver international : official journal of the International Association for the Study of the Liver · 2024
- Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.Cancer research · 2022
- Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.Journal of hematology & oncology · 2024
- METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.Cancer research · 2023
via PubMed
Wikidata facts
- Mass
- 426.109
Show 4 more facts
- chemical formula
- C₂₁H₁₉ClN₄O₄
- canonical SMILES
- COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
- World Health Organisation international non-proprietary name
- lenvatinib
- Commons category
- Lenvatinib
via Wikidata · CC0
~5 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- References
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
==Medical uses== Lenvatinib is approved (since 2015) for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).
Excerpted from Wikipedia’s “lenvatinib” article, available under the CC BY-SA 4.0 licence.